Associations of TP53 mutations, codon 72 polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients

Shi,Qi; Xiao,Kang; Wei,Wei; Zhang,Bao-Yun; Chen,Cao; Xu,Yin; Chen,Li-Na; Song,Yun-Tao; Ma,Xiao; Zhang,Nai-Song; Dong,Xiao-Ping

doi:10.3892/or.2013.2750

Associations of TP53 mutations, codon 72 polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients

Authors:
- Qi Shi
- Kang Xiao
- Wei Wei
- Bao-Yun Zhang
- Cao Chen
- Yin Xu
- Li-Na Chen
- Yun-Tao Song
- Xiao Ma
- Nai-Song Zhang
- Xiao-Ping Dong
View Affiliations

Affiliations: State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center of Infectious Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, P.R. China, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: September 20, 2013 https://doi.org/10.3892/or.2013.2750
Pages: 2811-2819

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the possible associations between mutations in TP53 and phenotypes of single-nucleotide polymorphisms (SNPs) in codon 72 (SNP72) with the expression profiles of p53 and human papillomavirus (HPV) infection, 93 pathologically diagnosed head and neck squamous cell carcinomas (HNSCCs) were included for study. Using PCR and direct sequencing, 45 TP53 mutations in 35 cases (37.6%) were confirmed out of the 93 HNSCCs. P53 immunohistochemistry (IHC) confirmed 34 (36.6%) cases with positive staining, including 22 cases with strong and 12 with weak positivity. IARC database and software analysis showed similar results that most of the mutated p53 proteins lost their normal function. Further statistical analysis found a negative correlation between p53 IHC and HPV IHC in the tissues from the group of other HNSCCs (of various sites other than the larynx) but not in the tissues from the laryngeal carcinomas. Analyses of SNP72 showed that the patients with the Arg phenotype had a significantly older age at disease onset when compared to patients with the Pro phenotype, particularly in the group of other HNSCCs. In addition, all cases with strong staining for p53 in the laryngeal carcinoma group had the Pro phenotype and all tumors with poor pathological differentiation in the group of other HNSCCs had the Pro phenotype. These data indicate that the profiles of TP53 mutations, SNP72 polymorphism, p53 IHC and HPV E6 IHC are distinct between the groups of laryngeal carcinoma and other HNSCCs.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
3	Sturgis EM and Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 110:1429–1435. 2007. View Article : Google Scholar : PubMed/NCBI
4	Wang Z, Sturgis EM, Zhang Y, et al: Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 131:E251–E258. 2012.PubMed/NCBI
5	Rautava J and Syrjänen S: Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol. 6(Suppl 1): S3–S15. 2012. View Article : Google Scholar : PubMed/NCBI
6	Braakhuis BJ, Snijders PJ, Keune WJ, et al: Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 96:998–1006. 2004. View Article : Google Scholar : PubMed/NCBI
7	Smeets SJ, Braakhuis BJ, Abbas S, et al: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 25:2558–2564. 2006. View Article : Google Scholar : PubMed/NCBI
8	Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer. 9:95–107. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI
10	Buyru N, Altinisik J, Isin M and Dalay N: p53 codon 72 polymorphism and HPV status in lung cancer. Med Sci Monit. 14:CR493–CR497. 2008.PubMed/NCBI
11	Storey A, Thomas M, Kalita A, et al: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 393:229–234. 1998. View Article : Google Scholar : PubMed/NCBI
12	Wei W, Shi Q, Guo F, et al: The distribution of human papillomavirus in tissues from patients with head and neck squamous cell carcinoma. Oncol Rep. 28:1750–1756. 2012.PubMed/NCBI
13	Kato S, Han SY, Liu W, et al: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 100:8424–8429. 2003. View Article : Google Scholar
14	SIFT Journal. http://sift.bii.a-star.edu.sg.
15	Tornesello ML, Buonaguro L and Buonaguro FM: Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol. 128:442–448. 2013.
16	Hollstein M, Moriya M, Grollman AP and Olivier M: Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res. Feb 17–2013.(Epub ahead of print). View Article : Google Scholar
17	Kannan K, Munirajan AK, Krishnamurthy J, et al: Low incidence of p53 mutations in betel quid and tobacco chewing-associated oral squamous carcinoma from India. Int J Oncol. 15:1133–1136. 1999.
18	Heinzel PA, Balaram P and Bernard HU: Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer. 68:420–423. 1996.PubMed/NCBI
19	Saranath D, Tandle AT, Teni TR, et al: p53 inactivation in chewing tobacco-induced oral cancers and leukoplakias from India. Oral Oncol. 35:242–250. 1999. View Article : Google Scholar : PubMed/NCBI
20	Lukas J, Bohr VA and Halazonetis TD: Cellular responses to DNA damage: current state of the field and review of the 52nd Benzon Symposium. DNA Repair. 5:591–601. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kilpivaara O and Aaltonen LA: Diagnostic cancer genome sequencing and the contribution of germline variants. Science. 339:1559–1562. 2013. View Article : Google Scholar : PubMed/NCBI
22	Bosch FX, Ritter D, Enders C, et al: Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer. 111:530–538. 2004. View Article : Google Scholar : PubMed/NCBI
23	Zhou W, Ma Y, Yang H, Ding Y and Luo X: A label-free biosensor based on silver nanoparticles array for clinical detection of serum p53 in head and neck squamous cell carcinoma. Int J Nanomedicine. 6:381–386. 2011. View Article : Google Scholar : PubMed/NCBI
24	Peltonen JK, Helppi HM, Pääkkö P, Turpeenniemi-Hujanen T and Vähäkangas KH: p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations. Head Neck Oncol. 2:362010. View Article : Google Scholar : PubMed/NCBI
25	Betiol J, Villa LL and Sichero L: Impact of HPV infection on the development of head and neck cancer. Braz J Med Biol Res. 46:217–226. 2013. View Article : Google Scholar : PubMed/NCBI
26	Tribius S and Hoffmann M: Human papilloma virus infection in head and neck cancer. Dtsch Arztebl Int. 110:184–190. 2013.PubMed/NCBI
27	Walter SD, Riddell CA, Rabachini T, Villa LL and Franco EL: Accuracy of p53 codon 72 polymorphism status determined by multiple laboratory methods: a latent class model analysis. PLoS One. 8:e564302013.
28	Chen SP, Hsu NY, Wu JY, et al: Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients. Ann Thorac Surg. 95:1196–1203. 2013. View Article : Google Scholar : PubMed/NCBI
29	Zhou X, Gu Y and Zhang SL: Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 13:4909–4914. 2012. View Article : Google Scholar : PubMed/NCBI
30	Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:809–819. 1997. View Article : Google Scholar : PubMed/NCBI
31	Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI
32	Li F, Sturgis EM, Chen X, Zafereo ME, Wei Q and Li G: Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer. 116:2350–2359. 2010.PubMed/NCBI